# Assessing the Safety, Tolerability and Pharmacokinetics(PK) of DZD9008 and the Effect of Low-fat Meal on PK of DZD9008 in Healthy Adult Participants

> **NCT04909242** · PHASE1 · COMPLETED · sponsor: **Dizal Pharmaceuticals** · enrollment: 78 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** DZD9008
- **DRUG:** Placebo
- **DRUG:** DZD9008
- **DRUG:** DZD9008

## Key facts

- **NCT ID:** NCT04909242
- **Lead sponsor:** Dizal Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-21
- **Primary completion:** 2022-02-07
- **Final completion:** 2022-02-07
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2022-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04909242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04909242, "Assessing the Safety, Tolerability and Pharmacokinetics(PK) of DZD9008 and the Effect of Low-fat Meal on PK of DZD9008 in Healthy Adult Participants". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT04909242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*